HC Wainwright Reaffirms Buy Rating for Altimmune (NASDAQ:ALT)

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 101.01% from the company’s previous close.

Other analysts have also issued research reports about the company. Stifel Nicolaus initiated coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Friday. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Altimmune Trading Up 0.8 %

NASDAQ:ALT opened at $5.97 on Tuesday. The company has a market cap of $459.77 million, a price-to-earnings ratio of -3.85 and a beta of 0.87. Altimmune has a twelve month low of $5.14 and a twelve month high of $11.16. The stock has a fifty day simple moving average of $6.45 and a 200-day simple moving average of $7.11.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. As a group, equities research analysts predict that Altimmune will post -1.35 EPS for the current fiscal year.

Insider Activity

In other news, CFO Gregory L. Weaver acquired 10,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were purchased at an average price of $5.20 per share, with a total value of $52,000.00. Following the transaction, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Altimmune

Institutional investors have recently bought and sold shares of the company. Larson Financial Group LLC purchased a new stake in shares of Altimmune during the 3rd quarter valued at $31,000. SBI Securities Co. Ltd. purchased a new stake in Altimmune in the fourth quarter valued at about $45,000. Virtus ETF Advisers LLC acquired a new stake in Altimmune in the fourth quarter worth about $60,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Altimmune during the fourth quarter worth about $72,000. Finally, 180 Wealth Advisors LLC purchased a new stake in shares of Altimmune during the fourth quarter worth about $78,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.